Eli Lilly & Co. (LLY) announced Friday morning that it has entered into a clinical trial collaboration with AstraZeneca (AZN). The companies will evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA, Lilly's VEGF Receptor 2 antiangiogenic cancer medicine.
Eli Lilly has been rising steadily since the open of trade Friday and is now up 1.69 at $78.10. The stock has broken out past resistance and has set a new high for the year.
For comments and feedback contact: editorial@rttnews.com